Mankind Pharma Limited has informed the Exchange regarding a press release dated July 31, 2025, titled "Please find attached Press Release".
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma reported Q1 FY26 revenue of INR 3,570 Cr, up 24.5% year-on-year, driven by 18.9% growth in domestic business and 81.1% surge in exports (boosted by BSV consolidation). EBITDA came in at INR 850 Cr with margins expanding modestly to 23.8% (up 20 bps YoY). However, profit after tax declined 17.4% YoY to INR 445 Cr, and diluted EPS fell 20.1% to INR 10.6, likely reflecting higher depreciation and finance costs from the BSV acquisition. The company maintained its #1 domestic rank with 4.9% market share and 1.8x volume outperformance versus the industry. Board approved an interim dividend of Rs 1 per share as Mankind marks 30 years of operations.
Strong top-line growth and market share gains are positive, but the sharp PAT decline despite EBITDA growth may raise investor concerns about acquisition-related costs. Interim dividend and volume outperformance provide some cushion for shareholders.